Key result
In ACS patients undergoing PCI, DAPT with prasugrel or ticagrelor for 12 or >12 months significantly reduced NACE compared to <12 months (6.7% and 7.2% vs 11.6%; p=0.003).
Why the study?
The benefits of short versus long-term DAPT with prasugrel or ticagrelor in ACS patients treated with PCI remain to be clearly defined, as current evidence is limited to clopidogrel-treated patients.
Does dual antiplatelet therapy for 12 months or longer reduce net adverse clinical events compared to shorter than 12 months in acute coronary syndrome patients treated with percutaneous coronary intervention and prasugrel or ticagrelor?
Cohort (n=4,424)
Does dual antiplatelet therapy for 12 months or longer reduce net adverse clinical events compared to shorter than 12 months in acute coronary syndrome patients treated with percutaneous coronary intervention and prasugrel or ticagrelor?
Absolute Event Rate: 7.2% vs 11.6%
p-value: p=0.003
In real-world ACS patients undergoing PCI, DAPT with prasugrel or ticagrelor for 12 months or longer reduces ischemic events and NACEs compared to shorter durations, though bleeding risk is increased, particularly in older and female patients.
No takes yet. Share an insight, caveat, or question.
Longer DAPT was associated with lower NACE in this cohort; leaves open whether extended therapy improves net outcomes in randomized trials.
D’Ascenzo et al. (2019) conducted a cohort in Acute coronary syndrome (n=4,424). Dual antiplatelet therapy (DAPT) for 12 months or >12 months vs. DAPT for <12 months was evaluated on Net adverse clinical events (NACEs) (p=0.003). In ACS patients undergoing PCI, DAPT with prasugrel or ticagrelor for 12 or >12 months significantly reduced NACE compared to <12 months (6.7% and 7.2% vs 11.6%; p=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: